Oct 11th 2013 - Edison Investment Research today published a report on 4SC entitled "Fine-tuning Pivotal HCC Trial Plans". In summary, the report says:
Baseline patient characteristics and the ZFP64 biomarker correlate with improved survival in liver cancer (HCC) subjects receiving resminostat. These findings will guide 4SC’s pivotal trial plans in front-line HCC. We are optimistic that 4SC can secure financing/partner to conduct the Phase IIb/III trial and model €789m peak sales. Our rNPV is unchanged at €122m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »